权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Comprehensive NeuroAIDS Core Center

综合神经艾滋病核心中心

基本信息

批准号：
8865677
负责人：
Kamel Khalili
金额：
$ 162.43万
依托单位：
TEMPLE UNIV OF THE COMMONWEALTH
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-08-05 至 2016-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8865677
关键词：
Acquired Immunodeficiency Syndrome Aftercare Animal Model Animals Area Basic Science Behavior Disorders Behavioral Biological Markers Caring Cell Culture Techniques Central Nervous System Diseases Clinical Clinical Investigator Clinical Sciences Communication Development Diagnostic Discipline Effectiveness Equation Evaluation Experimental Animal Model Feasibility Studies Fostering Funding Gene Expression Government HIV HIV-1 Individual Infection Inpatients Institution Investigation Laboratories Laboratory Finding Mammalian Cell Medical Medicine Mental Health Mental disorders Mentors Mentorship Microbiology Mission Modality Molecular Molecular Biology Molecular Medicine Neurodegenerative Disorders Neurologic Neurologic Dysfunctions Neurology Neurosciences Neurovirology Patients Pennsylvania Philadelphia Physicians Pilot Projects Proteomics Public Health Recruitment Activity Research Research Infrastructure Research Personnel Research Support Rest Scientist Seeds Services Structure Therapeutic Therapeutic Agents Time Training Translational Research United States National Institutes of Health Universities University Hospitals Validation Virus base bench to bedside in vivo innovation interdisciplinary approach medical schools multidisciplinary nervous system disorder neuroAIDS neurobehavioral disorder neurocognitive disorder neuropathology neuropsychiatry programs virology

项目摘要

This revised application seeks support to establish a Comprehensive NeuroAIDS Core Center (CNACC) at the Temple University School of Medicine in order to bring highly needed infrastructure for basic scientists and clinicians involved in HIV-1/AIDS research and neurological, neurodegenerative, and neurobehavioral disorders. The central theme of CNACC is structured based on our hypothesis that understanding the mechanisms of HIV-1/CNS interactions at the molecular, cellular, and experimental animal model levels and bidirectional communication of laboratory findings and clinical observations to validate basic science discoveries are prerequisites for the development of effective, safe, and reliable approaches for early diagnostics and therapeutics for AIDS-associated neurological dysfunctions. The CNACC will provide unprecedented infrastructure to a large group of neuroAIDS investigators who plan to pursue their objectives using multidisciplinary approaches in cell culture, small animal models, and in the clinical setting for assessing gene expression and biomarker identification at the cellular and molecular levels. Further, through the Developmental Core, the CNACC will provide a unique opportunity for training and mentoring of junior and clinical investigators and attract and develop physician scientists in the field of neuroAIDS. Through CNACC, we will provide start-up funds for new and innovative pilot projects of newly recruited, independent investigators and will support feasibility studies for more established neuroAIDS investigators. The funding through this center will create a unique infrastructure that will serve to enhance and extend the effectiveness of ongoing HIV-1 investigations and promote translational research in neuroAIDS at Temple and other medical institutions in the greater Philadelphia area that are involved in basic science and clinical AIDS research. With its comprehensive structural organization encompassing broadly based cores ranging from molecular biology to experimental animals to the clinical arena directed by skilled and highly competent investigators from various disciplines, CNACC will support research in a variety of areas such as virology, basic and behavioral neuroscience, and clinical science, all of which are aimed toward the discovery of better diagnostics and effective therapeutic agents toward AIDS/CNS disorders.

该修订后的申请寻求支持，以在坦普尔大学医学院建立一个综合性神经艾滋病核心中心（CNACC），以便为参与HIV-1/艾滋病研究和神经系统，神经退行性疾病和神经行为障碍的基础科学家和临床医生提供急需的基础设施。CNACC的中心主题是基于我们的假设，即在分子，细胞和实验动物模型水平上理解HIV-1/CNS相互作用的机制以及实验室发现和临床观察的双向交流以验证基础科学发现是开发有效，安全和可靠的方法用于早期诊断和治疗艾滋病相关神经功能障碍的先决条件。CNACC将为一大群神经艾滋病研究人员提供前所未有的基础设施，这些研究人员计划在细胞培养、小动物模型和临床环境中使用多学科方法来实现他们的目标，以在细胞和分子水平上评估基因表达和生物标志物鉴定。此外，通过发展核心，CNACC将为初级和临床研究人员的培训和指导提供独特的机会，并吸引和发展神经艾滋病领域的医生科学家。通过CNACC，我们将为新招募的独立研究人员的新的和创新的试点项目提供启动资金，并将支持更多成熟的神经艾滋病研究人员的可行性研究。通过该中心的资金将创建一个独特的基础设施，将有助于加强和扩大正在进行的HIV-1调查的有效性，并促进坦普尔和大费城地区其他医疗机构参与基础科学和临床艾滋病研究的神经艾滋病转化研究。CNACC拥有全面的结构组织，包括从分子生物学到实验动物到临床竞技场的广泛核心，由来自各个学科的熟练和高度胜任的研究人员指导，CNACC将支持病毒学，基础和行为神经科学以及临床科学等各个领域的研究，所有这些都旨在发现更好的诊断方法和有效的治疗AIDS/CNS疾病的药物。